Halia Therapeutics

Targeting LRRK2 and NEK7 to regulate NLRP3 inflammasome activation, a driver of systemic inflammation, gives Halia a shared mechanism for its RAB10-pathway therapy pipeline, which it began developing because inflammation underlies a wide range of chronic illnesses. Halia Therapeutics is a clinical-stage biopharmaceutical company developing medicines for patients with serious diseases.

Halia Therapeutics is advancing multiple programs into clinical trials across several disease areas. HT-6184 is being developed for patients with lower-risk myelodysplastic syndromes, a chronic blood disorder with limited non-toxic treatment options. HT-4253 is designed for early intervention in APOE4 carriers, who carry the highest genetic risk for Alzheimer’s disease.